Entrectinib

Major

Entrectinib Ibutilide Corvert An increased risk of QT interval prolongation Details Entrectinib Idelalisib Zydelig Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Iloperidone Fanapt An increased risk of QT interval prolongation Details Entrectinib Imatinib Gleevec Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Imipramine An increased risk of QT interval prolongation Details Entrectinib Indinavir Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Entrectinib Inotuzumab Ozogamicin Besponsa An increased risk of QT interval prolongation Details Entrectinib Isoflurane Fluriso An increased risk of QT interval prolongation and torsade de pointes Details Entrectinib Itraconazole Sporanox Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Ivabradine Corlanor An increased risk of QT interval prolongation Details Entrectinib Ivosidenib Tibsovo Reduced entrectinib exposure and efficacy and an increased risk of QT interval prolongation Details Entrectinib Lanreotide Altered exposure to CYP3A4 substrate Details Entrectinib Lapatinib Tykerb An increased risk of QT interval prolongation Details Entrectinib Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Entrectinib Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Entrectinib Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Entrectinib Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Entrectinib Lenvatinib Lenvima An increased risk of QT interval prolongation Details Entrectinib Letermovir Prevymis Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Leuprolide Eligard An increased risk of QT interval prolongation Details Entrectinib Levofloxacin Levaquin An increased risk of QT interval prolongation Details Entrectinib Lofexidine An increased risk of QT interval prolongation Details Entrectinib Lomitapide Increased lomitapide exposure Details Entrectinib Lonafarnib Zokinvy Increased entrectinib exposure, an increased frequency or severity of adverse reactions and an increased risk of QT interval prolo... Details Entrectinib Loperamide Diamode An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Entrectinib Lorlatinib Lorbrena Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Lumacaftor Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Lumefantrine Increased artemether/lumefantrine exposure and an increased risk of QT prolongation Details Entrectinib Macimorelin An increased risk of QT interval prolongation Details Entrectinib Mavorixafor Xolremdi Increased mavorixafor exposure, increased CYP3A4 substrate with NTI exposure, increased risk of mavorixafor-related adverse effect... Details Entrectinib Mefloquine Lariam® An increased risk of QT interval prolongation Details Entrectinib Methadone Diskets An increased risk of QT interval prolongation Details Entrectinib Methotrimeprazine An increased risk of QT interval prolongation Details Entrectinib Methylergonovine Methergine Increased methylergonovine exposure Details Entrectinib Metronidazole Flagyl An increased risk of QT interval prolongation Details Entrectinib Milsaperidone An increased risk of QT interval prolongation Details Entrectinib Mirtazapine Mirataz Increased risk of QT interval prolongation and torsades de pointes Details Entrectinib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Entrectinib Mitotane Lysodren Reduced entrectinib exposure and reduced efficacy of entrectinib Details